MCID: SBC017
MIFTS: 36

Sebaceous Gland Disease

Categories: Endocrine diseases, Skin diseases

Aliases & Classifications for Sebaceous Gland Disease

MalaCards integrated aliases for Sebaceous Gland Disease:

Name: Sebaceous Gland Disease 12 15
Sebaceous Gland Diseases 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9098
ICD10 33 L70.8
ICD9CM 35 706.1

Summaries for Sebaceous Gland Disease

Disease Ontology : 12 A skin disease that is located in the sebaceous gland.

MalaCards based summary : Sebaceous Gland Disease, also known as sebaceous gland diseases, is related to neurofibromatosis, type ii and mycobacterium chelonae, and has symptoms including pruritus and exanthema. An important gene associated with Sebaceous Gland Disease is PLIN2 (Perilipin 2), and among its related pathways/superpathways are IL-2 Pathway and IL-1 Family Signaling Pathways. The drugs leucovorin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and tonsil, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Sebaceous glands are microscopic exocrine glands in the skin that secrete an oily or waxy matter, called... more...

Related Diseases for Sebaceous Gland Disease

Diseases related to Sebaceous Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 neurofibromatosis, type ii 31.4 DEFB4A IL1A SHBG TLR2
2 mycobacterium chelonae 10.2 CXCL8 TLR2
3 mycobacterium marinum 10.2 CXCL8 TLR2
4 mycobacterium kansasii 10.2 CXCL8 TLR2
5 neurosyphilis 10.2 CXCL8 TLR2
6 47, xxy 10.2 AR SHBG
7 haemophilus influenzae 10.2 CXCL8 TLR2
8 postmenopausal atrophic vaginitis 10.2 AR SHBG
9 androgen insensitivity, partial 10.2 AR SHBG
10 meibomian cyst 10.2 AR PLIN2
11 clonorchiasis 10.2 CD79A CXCL8
12 anal fistula 10.2 DEFB4A MSH2
13 mycobacterium abscessus 10.1 CXCL8 TLR2
14 alopecia, androgenetic, 1 10.1 AR SHBG
15 otitis media 10.1 CD79A CXCL8 TLR2
16 cervicitis 10.1 CXCL8 DEFB4A
17 androgenic alopecia 10.1 AR SHBG
18 vulvovaginal candidiasis 10.1 CD79A DEFB4A TLR2
19 corneal abscess 10.1 AR DEFB4A
20 anal canal squamous cell carcinoma 10.1 NCSTN PSENEN
21 complete androgen insensitivity syndrome 10.1 AR SHBG
22 marasmus 10.1 IGF1 SHBG
23 female reproductive system disease 10.1 CXCL8 MSH2 SHBG
24 vaginal disease 10.1 CXCL8 DEFB4A
25 cone-rod dystrophy 12 10.1 IGF1 PLIN2
26 prostatic hyperplasia, benign 10.1 AR SHBG
27 sebaceous adenocarcinoma 10.1 AR MSH2 PLIN2
28 septic arthritis 10.1 CXCL8 DEFB4A TLR2
29 bacterial infectious disease 10.0 CXCL8 DEFB4A TLR2
30 sex differentiation disease 10.0 AR SHBG
31 intestinal disease 10.0 CXCL8 DEFB4A MSH2
32 sinusitis 10.0 CXCL8 DEFB4A
33 congenital hypogammaglobulinemia 10.0 CD79A IL1A
34 chronic graft versus host disease 10.0 CD79A IL1A
35 vaginitis 10.0 AR CXCL8 DEFB4A
36 leukoregulin 10.0 CXCL8 IL1A
37 scabies 10.0 CXCL8 IL1A
38 male reproductive organ cancer 10.0 AR IGF1 SHBG
39 male reproductive system disease 10.0 AR IGF1 SHBG
40 breast disease 10.0 IGF1 MSH2 SHBG
41 gonadal disease 10.0 AR IGF1 SHBG
42 sweat gland disease 9.9 NCSTN PSTPIP1
43 idiopathic inflammatory myopathy 9.9 AARS IL1A
44 cryptosporidiosis 9.9 CD79A IL1A
45 proteasome-associated autoinflammatory syndrome 1 9.9 CXCL8 IL1A TLR2
46 periodontitis 9.9 CXCL8 IL1A TLR2
47 leishmaniasis 9.9 CXCL8 IL1A TLR2
48 oral candidiasis 9.9 CXCL8 DEFB4A IL1A
49 reproductive system disease 9.8 AR CXCL8 IGF1 SHBG
50 chlamydia 9.8 CD79A CXCL8 IL1A TLR2

Graphical network of the top 20 diseases related to Sebaceous Gland Disease:



Diseases related to Sebaceous Gland Disease

Symptoms & Phenotypes for Sebaceous Gland Disease

UMLS symptoms related to Sebaceous Gland Disease:


pruritus, exanthema

MGI Mouse Phenotypes related to Sebaceous Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 AR CD79A IGF1 IL1A MSH2 NCSTN
2 immune system MP:0005387 9.81 AR CD79A IGF1 IL1A MSH2 NCSTN
3 integument MP:0010771 9.56 AARS AR IGF1 IL1A MSH2 NCSTN
4 neoplasm MP:0002006 9.17 AR CD79A IGF1 IL1A MSH2 NCSTN

Drugs & Therapeutics for Sebaceous Gland Disease

Drugs for Sebaceous Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 1 58-05-9 6006 143
2
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 1 80-08-0 2955
3
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
4
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
5
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-72-7 338
6
Isotretinoin Approved Phase 4,Phase 1,Not Applicable 4759-48-2 5538 5282379
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
8
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
9
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
10
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
11
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
12
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
13
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
14
Adapalene Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106685-40-9 60164
15
Zinc Approved, Investigational Phase 4 7440-66-6
16
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
17
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
18 tannic acid Approved Phase 4
19
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
20
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
21
Desogestrel Approved Phase 4 54024-22-5 40973
22
Norgestrel Approved Phase 4 6533-00-2 13109
23
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
24
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
25
Norgestimate Approved, Investigational Phase 4,Phase 1 35189-28-7 6540478
26 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
27
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
28
Cyproterone Acetate Approved, Investigational Phase 4,Phase 3 427-51-0
29
Coal tar Approved Phase 4,Not Applicable 8007-45-2
30
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 10118-90-8 5281021
31
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
32
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65277-42-1 3823 47576
33
Chamomile Approved, Experimental, Investigational Phase 4
34
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
35
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
37
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 302-79-4 5538 444795
38
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
39 Nadifloxacin Investigational Phase 4,Phase 3 124858-35-1
40
Rosemary Experimental Phase 4
41 Folate Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
43 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
44 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
45 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 Folic Acid Antagonists Phase 4,Phase 3,Phase 1
48 Antimalarials Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 392)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Unknown status NCT02944461 Phase 4 Dapsone 7.5 % gel
2 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
3 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
4 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
5 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
6 Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia Completed NCT03626298 Phase 4 Adapalene;Nicotinamide, ABA and Zinc PCA;Placebos
7 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
8 A Treatment for Severe Inflammatory Acne Subjects Completed NCT02899000 Phase 4 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel;Oral doxycycline hyclate
9 Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products Completed NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
10 Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
11 Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
12 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
13 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Completed NCT02524665 Phase 4
14 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
15 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
16 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
17 Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Completed NCT01951417 Phase 4 Adapalene/BPO Gel
18 Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
19 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne Completed NCT01706263 Phase 4 MAXCLARITY II (2.5% BPO) Foam Cleanser;MAXCLARITY II (2.5% BPO) Foam Treatment;MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
20 U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Completed NCT01706250 Phase 4
21 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
22 Effect of Samples on Acne Treatment With Epiduo® Gel Completed NCT01504204 Phase 4 Adapalene + benzoyl peroxide samples;Adapalene + benzoyl peroxide from standard tube
23 An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment Completed NCT01466673 Phase 4 Ethinyl estradiol/Norgestimate (EE/NGM);Ethinyl estradiol/Desogestrel (EE/DSG)
24 A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory Completed NCT01404130 Phase 4 Isotretinoin
25 Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin Completed NCT01387048 Phase 4 skinoren;differin;skinoren
26 A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products Completed NCT01313728 Phase 4 Dapsone plus Tretinoin Gel;Tretinoin Gel
27 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne Completed NCT01231334 Phase 4 Dapsone plus Adapalene;Clindamycin/benzoyl peroxide plus Adapalene
28 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
29 Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel Completed NCT01188538 Phase 4 Epiduo gel;BPO
30 Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
31 Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
32 A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris Completed NCT01016977 Phase 4 Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene;clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
33 Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications Completed NCT01015638 Phase 4 Clindamycin and BPO 5% gel;Clindamycin phosphate and benzoyl peroxide 2.5% gel.
34 Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications Completed NCT00964366 Phase 4 clindamycin and benzoyl peroxide;Dapsone gel
35 A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
36 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
37 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications Completed NCT00926367 Phase 4 Clindamycin and benzoyl peroxide;benzoyl peroxide 2.5% and adapalene 0.1% gel
38 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
39 A Study of Different Use Regimens Using Two Acne Treatments Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
40 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne Completed NCT00887484 Phase 4 BENZOYL PEROXIDE/ CLINDAMYCIN;BENZOYL PEROXIDE/ ADAPALENE
41 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne Completed NCT00841776 Phase 4 Duac;Ziana gel
42 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
43 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
44 Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne Completed NCT00807014 Phase 4 Duac Gel;Differin gel
45 Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring Completed NCT00795327 Phase 4
46 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
47 Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
48 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face. Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
49 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris Completed NCT00696449 Phase 4 Adapalene
50 Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel

Search NIH Clinical Center for Sebaceous Gland Disease

Genetic Tests for Sebaceous Gland Disease

Anatomical Context for Sebaceous Gland Disease

MalaCards organs/tissues related to Sebaceous Gland Disease:

41
Skin, Lung, Tonsil, Prostate, Pancreas

The Foundational Model of Anatomy Ontology organs/tissues related to Sebaceous Gland Disease:

19
The Sebaceous Gl

Publications for Sebaceous Gland Disease

Articles related to Sebaceous Gland Disease:

# Title Authors Year
1
Primary sebocytes and sebaceous gland cell lines for studying sebaceous lipogenesis and sebaceous gland diseases. ( 29451719 )
2018
2
New pharmaceutical concepts for sebaceous gland diseases: implementing today's pre-clinical data into tomorrow's daily clinical practice. ( 22250709 )
2012
3
Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescents. ( 18837699 )
2008

Variations for Sebaceous Gland Disease

Expression for Sebaceous Gland Disease

Search GEO for disease gene expression data for Sebaceous Gland Disease.

Pathways for Sebaceous Gland Disease

Pathways related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 CD79A IGF1 IL1A NCSTN PSENEN TLR2
2
Show member pathways
11.92 CXCL8 IL1A TLR2
3
Show member pathways
11.88 IL1A NCSTN PSENEN
4
Show member pathways
11.85 CXCL8 DEFB4A TLR2
5 11.82 AR CXCL8 IL1A
6 11.52 CXCL8 IGF1 IL1A
7 11.39 CXCL8 IL1A TLR2
8 10.79 AR IGF1 IL1A
9 10.77 NCSTN PSENEN
10 10.62 AR SHBG
11 10.03 CXCL8 NCSTN PSENEN

GO Terms for Sebaceous Gland Disease

Cellular components related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gamma-secretase complex GO:0070765 8.62 NCSTN PSENEN

Biological processes related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.84 CXCL8 DEFB4A IL1A TLR2
2 negative regulation of cell proliferation GO:0008285 9.81 AR CXCL8 IL1A TLR2
3 positive regulation of gene expression GO:0010628 9.78 AR IGF1 IL1A TLR2
4 inflammatory response GO:0006954 9.76 CXCL8 IL1A PSTPIP1 TLR2
5 positive regulation of mitotic nuclear division GO:0045840 9.52 IGF1 IL1A
6 membrane protein ectodomain proteolysis GO:0006509 9.49 NCSTN PSENEN
7 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 AR IGF1
8 cell activation GO:0001775 9.4 IGF1 TLR2
9 response to molecule of bacterial origin GO:0002237 9.37 CXCL8 TLR2
10 amyloid precursor protein metabolic process GO:0042982 9.32 NCSTN PSENEN
11 Notch receptor processing GO:0007220 9.26 NCSTN PSENEN
12 amyloid precursor protein catabolic process GO:0042987 9.16 NCSTN PSENEN
13 Notch receptor processing, ligand-dependent GO:0035333 8.96 NCSTN PSENEN
14 amyloid-beta formation GO:0034205 8.62 NCSTN PSENEN

Molecular functions related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 AR SHBG
2 androgen binding GO:0005497 8.62 AR SHBG

Sources for Sebaceous Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....